Back to top
more

Ironwood Pharmaceuticals (IRWD)

(Real Time Quote from BATS)

$4.20 USD

4.20
642,909

-0.09 (-2.10%)

Updated Aug 24, 2026 01:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (102 out of 247)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Kinjel Shah headshot

5 Small Drug Stocks to Buy as Industry Recovery Picks Up

by Kinjel Shah

Innovation is at its peak in the Zacks Medical-Drugs industry. SLNO, NKTR, RIGL, IRWD and MRKR may prove to be good additions to one's portfolio.

Zacks Equity Research

Ironwood Stock Rises 27% on Upbeat Revenue Guidance for 2026

by Zacks Equity Research

IRWD shares jump on upbeat 2026 revenue guidance amid rising Linzess demand in the United States. The company also provides a key pipeline update.

Zacks Equity Research

Why Is Ironwood (IRWD) Up 24.9% Since Last Earnings Report?

by Zacks Equity Research

Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Kanishka Das headshot

IRWD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Pick?

by Kanishka Das

Ironwood and Puma Biotechnology are advancing therapies for gastrointestinal disorders and cancer, respectively. Rising sales of key drugs fuel 2026 prospects.

Kanishka Das headshot

Can Linzess Continue to Aid IRWD's Top Line After a Strong Q3?

by Kanishka Das

Ironwood gains momentum as rising U.S. demand for Linzess drives strong profit growth during the third quarter.

Kanishka Das headshot

IRWD Rises 110% in a Month: Should You Buy, Sell or Hold the Stock?

by Kanishka Das

Ironwood's 110% monthly surge follows upbeat third-quarter results and raised 2025 outlook, powered by increasing Linzess demand.

Zacks Equity Research

IRWD Beats on Q3 Earnings & Revenues, Raises 2025 View, Stock Soars

by Zacks Equity Research

Ironwood posts a stellar third-quarter beat with higher revenues and raises 2025 outlook on Linzess-driven strength.

Zacks Equity Research

Ironwood Pharmaceuticals (IRWD) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Ironwood (IRWD) delivered earnings and revenue surprises of +166.67% and +78.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Xencor (XNCR) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Xencor (XNCR) delivered earnings and revenue surprises of +88.89% and -18.15%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Xeris Biopharma Holdings, Inc. (XERS) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Xeris Biopharma (XERS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.